SLC2A13 Antibody (Center) Blocking peptide
Synthetic peptide
Catalog # BP13677c

Specification

SLC2A13 Antibody (Center) Blocking peptide - Product Information

Primary Accession   Q96QE2

SLC2A13 Antibody (Center) Blocking peptide - Additional Information

Gene ID 114134

Other Names
Proton myo-inositol cotransporter, H(+)-myo-inositol cotransporter, Hmit, H(+)-myo-inositol symporter, Solute carrier family 2 member 13, SLC2A13

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP13677c was selected from the Center region of SLC2A13. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

SLC2A13 Antibody (Center) Blocking peptide - Protein Information

Name SLC2A13 (HGNC:15956)

Function
H(+)-myo-inositol cotransporter (PubMed:11500374). Can also transport related stereoisomers (PubMed:11500374).

Cellular Location
Cell membrane; Multi-pass membrane protein

Tissue Location
Predominantly expressed in the brain.

SLC2A13 Antibody (Center) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

SLC2A13 Antibody (Center) Blocking peptide - Images

SLC2A13 Antibody (Center) Blocking peptide - Background

H(+)-myo-inositol cotransporter.It can also transport related stereoisomers.

SLC2A13 Antibody (Center) Blocking peptide - References

Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Bankovic, J., et al. Lung Cancer 67(2):151-159(2010)Satake, W., et al. Nat. Genet. 41(12):1303-1307(2009)Di Daniel, E., et al. BMC Cell Biol. 10, 54 (2009) :Barrett, J.C., et al. Nat. Genet. 40(8):955-962(2008)